Accueil>>Signaling Pathways>> Others>>Aspartyl-alanyl-diketopiperazine

Aspartyl-alanyl-diketopiperazine (Synonyms: DA-DKP)

Catalog No.GC35410

L'aspartyl-alanyl-dicétopipérazine (DA-DKP) est une molécule immunomodulatrice générée par clivage et cyclisation À partir de l'extrémité N-terminale de l'albumine humaine et peut moduler la réponse immunitaire inflammatoire par une voie moléculaire impliquée dans l'anergie des lymphocytes T .

Products are for research use only. Not for human use. We do not sell to patients.

Aspartyl-alanyl-diketopiperazine Chemical Structure

Cas No.: 110954-19-3

Taille Prix Stock Qté
10mM (in 1mL DMSO)
357,00 $US
En stock
5mg
324,00 $US
En stock
10mg
510,00 $US
En stock
50mg
1 530,00 $US
En stock
100mg
2 457,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Aspartyl-alanyl-diketopiperazine (DA-DKP) is an immunomodulatory molecule generated by cleavage and cyclization from the N-terminus of human albumin and can modulate the inflammatory immune response through a molecular pathway implicated in T- lymphocyte anergy[1][2].

[1]. Bar-Or D, et al. Dipeptidyl peptidase IV activity in commercial solutions of human serum albumin. Anal Biochem. 2013 Oct 1;441(1):13-7. [2]. Shimonkevitz R, et al. A diketopiperazine fragment of human serum albumin modulates T-lymphocyte cytokine production through rap1. J Trauma. 2008 Jan;64(1):35-41.

Avis

Review for Aspartyl-alanyl-diketopiperazine

Average Rating: 5 ★★★★★ (Based on Reviews and 7 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Aspartyl-alanyl-diketopiperazine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.